All Comments by Michael Wolfe

  1. Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production.
  2. Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production.
  3. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease.
  4. The crystal structure of GXGD membrane protease FlaK.
  5. Three-amino acid spacing of presenilin endoproteolysis suggests a general stepwise cleavage of gamma-secretase-mediated intramembrane proteolysis.
  6. Functional analysis of the transmembrane domains of presenilin 1: participation of transmembrane domains 2 and 6 in the formation of initial substrate-binding site of gamma-secretase.
  7. Beta-amyloid precursor protein mutants respond to gamma-secretase modulators.
  8. An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production.
  9. Dual Secretase Approach Shows Promise in AD Mice
  10. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment.
  11. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury.
  12. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons.
  13. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
  14. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases.
  15. Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains.